National Health Act 1953 - Amendment determination under sections 85, 85a and 88 - pharmaceutical benefits (No. PB 87 of 2009) (Cth)

COMMONWEALTH OF AUSTRALIA

Instrument number PB 87 of 2009

Amendment determinations under sections 85, 85A and 88 of the National Health Act 1953

I, LINDA JACKSON, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under sections 85, 85A and 88 of the National Health Act 1953.

Dated 3 September 2009

LINDA JACKSON

Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing

Amendment determination — pharmaceutical benefits

1              Commencement

This instrument commences on 1 October 2009.

2              Amendment of PB 114 of 2008

Schedule 1 amends PB 114 of 2008.

Schedule 1            Amendments

1. Part 1 of Schedule 1, item dealing with Alprazolam in the form Tablet 2 mg

in the column headed “Brand” insert in alphabetical order:

Alprazolam-GA

1. Part 1 of Schedule 1, item dealing with Amino acid formula without phenylalanine

omit from the columns in the order indicated:

Oral powder 250 g (PK AID II) Oral 8 5 PK AID II

1. Part 1 of Schedule 1, item dealing with Amino acid formula with vitamins and minerals without phenylalanine

(a) omit from the columns in the order indicated:

Oral liquid 62.5 mL, 60 (Lophlex LQ 10) Oral 2 5 Lophlex LQ 10

and substitute:

Oral liquid 62.5 mL, 60 (PKU Lophlex LQ 10) Oral 2 5 PKU Lophlex LQ 10

(b) omit from the columns in the order indicated:

Oral liquid 125 mL, 30 (Lophlex LQ) Oral 3 5 Lophlex LQ

and substitute:

Oral liquid 125 mL, 30 (PKU Lophlex LQ 20) Oral 3 5 PKU Lophlex LQ 20

1. Part 1 of Schedule 1, item dealing with Amisulpride in the form Tablet 400 mg

in the column headed “Brand” insert in alphabetical order:

Sulprix

1. Part 1 of Schedule 1, item dealing with Cephalexin in the forms Capsule 250 mg (anhydrous) and Capsule 500 mg (anhydrous)

omit from the column headed “Brand”:

Sporahexal

1. Part 1 of Schedule 1, item dealing with Citalopram in the form Tablet 20 mg (as hydrobromide)

in the column headed “Brand” insert in alphabetical order:

Citalopram generichealth

1. Part 1 of Schedule 1, item dealing with Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 25 mg

omit from the column headed “Brand”:

Dinac

1. Part 1 of Schedule 1, item dealing with Gabapentin in the form Capsule 100 mg

in the column headed “Brand” insert in alphabetical order:

APO-Gabapentin

1. Part 1 of Schedule 1, item dealing with Gabapentin in the form Capsule 300 mg

omit from the column headed “Brand”:

Pendine 300

1. Part 1 of Schedule 1, item dealing with Gliclazide in the form Tablet 80 mg

omit from the column headed “Brand”:

Diamicron

1. Part 1 of Schedule 1, item dealing with Naloxone

omit from the columns in the order indicated:

Injection containing naloxone hydrochloride 800 micrograms in 2 mL disposable injection set Injection 1 .. Naloxone Min-I-Jet

1. Part 1 of Schedule 1, item dealing with Omeprazole in the form Tablet 20 mg

in the column headed “Brand” insert in alphabetical order:

Ozmep

1. Part 1 of Schedule 1, item dealing with Oxaliplatin in the forms Powder for I.V. infusion 50 mg and Powder for I.V. infusion 100 mg

in the column headed “Brand” insert in alphabetical order:

Oxaliplatin Alphapharm

1. Part 1 of Schedule 1, item dealing with Simvastatin in the form Tablet 10 mg

in the column headed “Brand” insert in alphabetical order:

Simvastatin-GA 10

1. Part 1 of Schedule 1, item dealing with Testosterone

omit from the columns in the order indicated:

Injection containing testosterone esters (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaprate, 100 mg testosterone decanoate) in    1 mL Injection 3 3 Sustanon 250

and substitute:

Injection containing testosterone esters (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg
testosterone isocaproate, 100 mg testosterone decanoate) in 1 mL Injection 3 3 Sustanon 250

1. Part 1 of Schedule 1, item dealing with Topiramate in the forms Tablet 25 mg, Tablet 50 mg, Tablet 100 mg and Tablet 200 mg

(a)  in the column headed “Brand” insert in alphabetical order:

APO-Topiramate

(b)  in the column headed “Brand” insert in alphabetical order:

Tamate

(c)  in the column headed “Brand” insert in alphabetical order:

Topiramate Sandoz

1. Part 2 of Schedule 1, item dealing with Omeprazole in the form Tablet 20 mg

in the column headed “Brand” insert in alphabetical order:

Ozmep

1. Part 2 of Schedule 1, item dealing with Simvastatin in the form Tablet 10 mg

in the column headed “Brand” insert in alphabetical order:

Simvastatin-GA 10

1. Part 1 of Schedule 2, item dealing with Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 25 mg

omit from the column headed “Brand”:

Dinac

1. Part 2 of Schedule 2, item dealing with Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 25 mg

omit from the column headed “Brand”:

Dinac

1. Part 1 of Schedule 3, item dealing with Cephalexin in the forms Capsule 250 mg (anhydrous) and Capsule 500 mg (anhydrous)

omit from the column headed “Brand”:

Sporahexal

1. Part 1 of Schedule 3, item dealing with Diclofenac in the form Tablet (enteric coated) containing diclofenac sodium 25 mg

omit from the column headed “Brand”:

Dinac

1. Part 1 of Schedule 3, item dealing with Naloxone

omit from the columns in the order indicated:

Injection containing naloxone hydrochloride 800 micrograms in 2 mL disposable injection set Injection 1 .. Naloxone Min-I-Jet